Recent Updates
Recently added Catalysts

AZD3632

Phase 1

Acute Lymphoblastic Leukaemia | Small molecule | Oncology |AstraZeneca PLC|Last Updated: Jul 20, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
CONTROLLED
Total Trials1
Total Enrollment84
FDA Designations
No designations recorded
Clinical trial landscape

AZD3632 · 1 trial · 3 indications

Phase 1 1
NCT07155226Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX OverexpressionAcute Lymphoblastic Leukaemia
RECRUITING84 Analytics
PHASE1RECRUITING
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic Leukaemia
NCT0715522684
Unlock trial analytics
Study Endpoints
Primary Endpoints
Module 1: Number of participants with dose-limiting toxicity (DLT)
At the end of Cycle 1 (each cycle is 28 days)

Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.

Module 1 and Module 2: Number of participants with dose modification, delay and discontinuations due to adverse events (AEs)
Up to 3 years 1 month

Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.

Module 1 and Module 2: Number of participants with treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs) and serious adverse vents (SAEs)
Up to 30 days after last dose (approximately 3 years 1 month)

Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed. Adverse events will be defined as treatment-emergent if they have an onset or worsen (by investigator report of a change in intensity) during the study treatment or the safety follow-up period but prior to any subsequent cancer therapy.

Secondary Endpoints
Module 1 and Module 2: Maximum concentration (Cmax) of AZD3632
From Day 1 to 3 years 1 month
Module 1 and Module 2: Time of maximum concentration (Tmax) of AZD3632
From Day 1 to 3 years 1 month
Module 1: Trough concentration (Ctrough) of AZD3632
From Day 1 to 3 years 1 month
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Module 1: AZD3632 dose 1EXPERIMENTALParticipants will receive AZD3632 (dose 1) through the treatment period.
Module 1: AZD3632 dose 2EXPERIMENTALParticipants will receive AZD3632 (dose 2) through the treatment period.
Module 1: AZD3632 dose 3EXPERIMENTALParticipants will receive AZD3632 (dose 3) through the treatment period.
Module 1: AZD3632 dose 4EXPERIMENTALParticipants will receive AZD3632 (dose 4) through the treatment period.
Module 1: AZD3632 dose 5EXPERIMENTALParticipants will receive AZD3632 (dose 5) through the treatment period.
Module 1: AZD3632 dose 6EXPERIMENTALParticipants will receive AZD3632 (dose 6) through the treatment period.
Module 2: AZD3632 + posaconazoleEXPERIMENTALParticipants will receive AZD3632 alone, then will receive AZD3632 in combination with posaconazole through treatment period.
Interventions
NameTypeDescription
AZD3632DRUGAZD3632 will be administered orally.
PosaconazoleDRUGPosaconazole will be administered orally.
Unlock Study Design Details
Eligibility Criteria
Age Range16 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites30

Key Inclusion Criteria: Core criteria: * Adequate organ function. * Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Module 1: * Advanced haematologic malignan...

Countries:United StatesAustraliaCanadaDenmarkGermanyItalyJapanSouth KoreaUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJul 20, 2026NCT07155226lastUpdatePostDate: changed
LOWJul 20, 2026NCT07155226lastUpdatePostDate: changed
LOWJun 18, 2026NCT07155226lastUpdatePostDate: changed
LOWJun 18, 2026NCT07155226lastUpdatePostDate: changed
LOWJun 18, 2026NCT07155226lastUpdatePostDate: changed
LOWJun 18, 2026NCT07155226lastUpdatePostDate: changed
LOWMay 26, 2026NCT07155226primaryCompletionDate: changed
LOWMay 24, 2026NCT07155226studyFirstPostDate: changed